Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa

Veterinary Microbiology

Volumn 119, Issue 2-4, 2007, Pages 304-310

  Pasquali, Frédérique ^a   Manfreda, Gerardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

E. coli; Fluoroquinolones; MPC; P. aeruginosa; S. Typhimurium

Indexed keywords

AGAR; CIPROFLOXACIN; ENROFLOXACIN; INHIBITOR PROTEIN; PHENYLALANYLARGININE BETA NAPHTHYLAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); ESCHERICHIA COLI; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR GENETICS; NONHUMAN; PARC GENE; PHENOTYPE; POINT MUTATION; PREVALENCE; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SEQUENCE ANALYSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; GENE AMPLIFICATION; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; TREATMENT OUTCOME;

ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM;

EID: 33845879085     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2006.08.018     Document Type: Article

References (23)

1. Akasaka T., Tanaka M., Yamaguchi A., and Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45 (2001) 2263-2268
2. Allen G.P., Kaatz G.W., and Rybak M.J. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int. J. Antimicrob. Agents 24 (2004) 150-160
3. Blondeau J.M., Hansen G., Metzler K., and Hedling P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 3 (2004) 1-19
4. Blondeau J.M., Zhao X., Hansen G., and Dlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 5 (2001) 433-438
5. Dong Y., Zhao X., Kreiswirth B.N., and Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44 (2000) 2581-2584
6. Drlica K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52 (2003) 11-17
7. Everett M.J., Jin Y.F., Ricci V., and Piddock L.J. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40 (1996) 2380-2386
8. Giraud E., Brisabois A., Martel J.L., and Chaslus-Dancla E. Comparative studies of mutation in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob. Agents Chemother. 43 (1999) 2131-2137
9. Hansen G.T., Zhao X., Drlica K., and Blondeau J.M. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 27 (2006) 120-124
10. Hopkins K.L., Davies R.H., and Threlfall E.J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int. J. Antimicrob. Agents 25 (2005) 358-373
11. Linde H.J., and Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J. Antimicrob. Chemother. 53 (2004) 252-257
12. Lomovskaya O., Lee A., Hoshino K., Ishida H., Mistry A., Warren M.S., Boyer E., Chamberland S., and Lee V.J. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43 (1999) 1340-1346
13. Lu T., Zhao X., Li X., Hansen G., Blondeau G., and Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J. Antimicrob. Chemother. 52 (2003) 61-64
14. Marcusson L.L., Olofsson S.K., Lindgren P.K., Cars O., and Hughes D. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. Journal of Antimicrob. Chemother. 55 (2005) 938-943
15. Metzler K., Hansen G.M., Hedlin P., Harding E., Drlica K., and Blondeau G.M. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24 (2004) 161-167
16. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals-Second edition: Approved standard M31-A2 (2002), NCCLS, Wayne, PA, USA
17. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth International Supplement M100-S14 (2004), NCCLS, Wayne, PA, USA
18. Olofsson S.K., Marcusson L.L., Komp Lindgren P., Hughes D., and Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57 (2006) 1116-1121
19. Ovando H.G., Gorla N., Luders C., Poloni G., Errecalde C., Prieto G., and Puellers I. Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens. J. Vet. Pharmacol. Therap. 22 (1999) 209-212
20. Randall L.P., Cooles S.W., Piddock L.J., and Woodward M.J. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J. Antimicrob. Chemother. 54 (2004) 688-691
21. Rodriguez J.C., Cebrian L., Lopez M., and Royo G. Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections. Int. J. Antimicrob. Agents 24 (2004) 352-356
22. Scheetz M.H., Bolon M.K., Scarsi K.K., Fotis M.A., and Postelnick M.J. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia. J. Infect. 52 (2006) 105-110
23. Smith H.J., Walters M., Hisanaga T., Zhanel G.G., and Hoban D.J. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 48 (2004) 3954-3958